Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy receives final approval for allergy tablets
The Office of Generic Drugs, FDA, has determined the Ohm formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Zyrtec
The Office of Generic Drugs, FDA, has determined the Ohm formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Zyrtec
Stating that they are cooperating fully with the investigating authorities, both the companies denied any misconduct on their part in the program. Denying any role of its employees
According to GlaxoSmithKline (GSK), the INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study is the first to investigate differences in exacerbation rates and related outcomes
The license includes trademarks and a few assets of the products. The company said that the other brands and consumer health team will continue to be part of
The vascular imaging system allows physicians, nurses and other health care professionals to clearly see accessible vasculature (or lack thereof) in real time. The device will use a
MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design of the Phase I clinical study on January 16,
Mr Shatar has completed his LLB and bachelor of economics from Monash University, Melbourne, Australia. Mr Shatar most recently served as the managing director of ICI Paints Malaysia.
Curis will receive an initial payment of $1 million, which is net of a payment to be made by Curis to a former third-party collaborator of Creative BioMolecules,
In June 2003, Millennium entered into an agreement with Ortho Biotech Products to collaborate on the commercialization and continued clinical development of Velcade. Under the terms of the
The company said that the Livian cardiac resynchronization therapy defibrillator (CRT-D), which is available in high-energy and standard-energy models, enables clinicians to customize therapy based on a patient’s